Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | 10% owner | December 01, 2023 | December 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date December 01, 2023 · Filed December 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2033-11-30 | Direct | 100,000 |
Reported balance
After 2023-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-01 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares subject to the option will vest as follows: 25% of the shares will vest on October 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as follows: 25% of the shares will vest on October 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 5, 2023 18:57 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-23-057548 · doc4.xml · derivative · entry 1 Ansari Aseem Z. · CIK 0001849177 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-11-30 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 25% of the shares will vest on October 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.